You are currently viewing a new version of our website. To view the old version click .
  • Review
  • Open Access

9 August 2018

Exposure to Environmental and Occupational Particulate Air Pollution as a Potential Contributor to Neurodegeneration and Diabetes: A Systematic Review of Epidemiological Research

,
,
and
1
Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh EH14 4AS, UK
2
Maxwell Institute for Mathematical Sciences, School of Mathematical and Computer Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK
3
Institute of Occupational Medicine (IOM), Riccarton, Edinburgh EH14 4AP, UK
*
Author to whom correspondence should be addressed.
This article belongs to the Section Occupational Safety and Health

Abstract

It has been hypothesised that environmental air pollution, especially airborne particles, is a risk factor for type 2 diabetes mellitus (T2DM) and neurodegenerative conditions. However, epidemiological evidence is inconsistent and has not been previously evaluated as part of a systematic review. Our objectives were to carry out a systematic review of the epidemiological evidence on the association between long-term exposure to ambient air pollution and T2DM and neurodegenerative diseases in adults and to identify if workplace exposures to particles are associated with an increased risk of T2DM and neurodegenerative diseases. Assessment of the quality of the evidence was carried out using the GRADE system, which considers the quality of the studies, consistency, directness, effect size, and publication bias. Available evidence indicates a consistent positive association between ambient air pollution and both T2DM and neurodegeneration risk, such as dementia and a general decline in cognition. However, corresponding evidence for workplace exposures are lacking. Further research is required to identify the link and mechanisms associated with particulate exposure and disease pathogenesis and to investigate the risks in occupational populations. Additional steps are needed to reduce air pollution levels and possibly also in the workplace environment to decrease the incidence of T2DM and cognitive decline.

1. Introduction

Globally, there is an estimated 2.3 million deaths every year attributed to work, with 86.9% of these attributed to work-related diseases []. In Britain, deaths from workplace exposure to chemicals, dusts, and fibres have increased over the last 40 years, with currently around 13,000 premature deaths each year from occupational lung disease and cancer []. The non-occupational environment can also have detrimental impacts on health. More specifically, individuals are exposed to many risk factors in their homes and in the environment such as air pollution, chemicals, ionising and non-ionising radiation, and noise. Exposure to air pollution is a particular concern to the public; with 91% of the world’s population living in areas where air quality is poor and exceeds World Health Organisation (WHO) guideline limits [].
Overall occupational and environmental exposures account for around 12.5% of the total global mortality each year. Within this, it is estimated that air pollution is responsible for around 3.2% of the disease burden, which, according to WHO, accounts for an estimated 4.2 million deaths per year worldwide due to stroke, heart disease, lung cancer, and chronic respiratory diseases [,]. Outdoor air pollution contributes about 40,000 early deaths each year in the UK [].
Ambient particulate air pollution, such as PM10, has been a public health concern in Britain since the ‘London Smog’ in 1952, when increased mortality and morbidity were reported soon after the event []. Similar incidents have occurred in Belgium (1930) and in Pennsylvania (1948) []. PM10 is particulate matter 10 micrometres or less in diameter and has a complex composition, with the ultrafine particle component held principally accountable for eliciting much of the toxicity associated with PM10 exposure [,]. Epidemiological studies indicate links between PM10 and PM2.5 with both short-term and long-term health effects []. Furthermore, both short-term (e.g., hours) and long-term exposure (e.g., months, years) can increase morbidity and mortality []. The link between PM10 and adverse health effects was first established in the 1990s, where epidemiological studies found a positive association between the level of particulate air pollution in cities and increased morbidity and mortality rates in both adults and children, with adverse health effects being manifested predominantly in susceptible individuals who had pre-existing pulmonary or cardiovascular disease [,]. It is now widely accepted that exposure to PM10 may cause or exacerbate allergic respiratory diseases (e.g., asthma) [], chronic obstructive pulmonary disease, pneumonia, and cardiovascular disease [] and is also defined as a definite carcinogen by International Agency for Research on Cancer (IARC) []. The cellular and molecular mechanisms underlying the toxicity of inhaled particles has been extensively investigated, and hypothesised to be driven by the stimulation of inflammation and/or oxidative stress [].
More recently, there has also been evidence from epidemiological and laboratory studies that long-term exposure to particulate air pollution is associated with T2DM [,,,,,,,,], dementia [,,], and other neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) [,]. The ability of inhaled particles to stimulate adverse effects in extrapulmonary sites has been reviewed previously [], and likely to manifest due to (i) the translocation of particles from the lung to other target sites, or (ii) release of mediators (e.g., cytokines) from the lung which act systemically [,].
The WHO estimates that 422 million people worldwide have diabetes, 47 million people are living with dementia and more than 10 million people are living with PD with increasing incidence expected over coming years.
As the world’s population is ageing, dementia has become a major public health concern. Most cases of neurological diseases are sporadic, and thus identification that particulate air pollution may be an important environmental risk factor may help better understand the aetiology of neurodegenerative disorders.
Diabetes is a metabolic disease, with different types (type 1 and type 2). Type 1 is often diagnosed in childhood and cannot be controlled without taking insulin, whereas type 2 is usually diagnosed in over 30 year olds and can generally be controlled with medication, or diet and exercise. Increasing evidence indicates that environmental exposures may cause diabetes and more recently T2DM [].
In addition to particle exposure via the environment, workplace exposures to particles can also occur. Workplace exposures can include a range of fine dusts and diesel exhaust. Accordingly, it is possible that exposure to particles in an occupational setting may also increase risk of T2DM and neurodegenerative disease.
The aim of this review is to systematically explore the association between long-term exposure (years/decades) to airborne particulate matter, both from ambient environmental pollutants and workplace exposures, and T2DM and cognitive impairment; earlier onset of greater than age-related decline and/or neurodegeneration in adults. The information from the review is discussed in relation to occupational exposure to particulate matter and fumes, and risk of dementia and diabetes. We hypothesise that exposure to ambient fine airborne particles is associated with an increased risk of neurodegenerative conditions and T2DM, and that these risks also apply to workplace exposures to particulate matter.

2. Methods

2.1. Search Strategy and Study Selection

PubMed, Web of Science, Scopus, and Google Scholar were searched (last search, March 2018) for studies using different combinations of search terms, related to diabetes (‘diabetes mellitus’, ‘type 2 diabetes mellitus’, ‘diabetes mellitus’, and ‘insulin resistance’), neurodegenerative diseases (‘dementia’, ‘neurodegeneration’, ‘Alzheimer’s Disease’, ‘Parkinson’s Disease’, ‘cognitive decline’, ‘cognitive impairment’, and ‘neurocognitive disorders’), air pollution (‘air pollution’, ‘outdoor air pollution’, ‘traffic-related air pollution’, ‘air pollutants’, ‘ambient air pollution’, and ‘environmental pollution’), airborne particles (‘particulate matter’, ‘PM10’, ‘PM2.5’, ‘fine particulate matter’, ‘airborne particulate matter’, ‘ambient particulate matter, ‘ultrafine particles’, ‘black carbon’, ‘black smoke’, and ‘elemental carbon’), and finally occupational exposure (‘occupational exposure’, ‘work exposure’, ‘employment exposure’, and ‘exposure at workplace’).
There were five combinations of search. First, air pollution and airborne particle terms were combined with diabetes terms and then with neurodegeneration disease terms. The third and fourth searches combined occupational exposure and diabetes and then neurodegeneration diseases, while the fifth search was a combination of diabetes and neurodegeneration disease terms. These five categories identified 10,084 articles. After de-duplication 7778 articles remained. First titles and then abstracts were screened for eligibility and potentially relevant articles were retrieved as full texts. The target population was adults, therefore all the studies that examined the associations in children were excluded. Articles were also excluded if they focused on pulmonary disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, lung disease, atherosclerosis, type-1 diabetes, vascular dementia, chemical exposures, organic solvents and pollutants, metals, smoking, asthma, birth outcomes, children, hypertension, different types of cancer, organic dust, bio-aerosols, allergic respiratory diseases, myocardial infraction, multiple sclerosis, diet, stroke, disease because of virus, asbestos, short-term (months) exposure to particles, pesticides, magnetic fields, welding fumes, bacterial inflammation, ozone, and nitric oxides. For articles without an abstract or enough information in the abstract to make a decision, the full text, and where necessary supplementary materials, were reviewed before a decision was made. We ended with 305 articles, separated into the five categories, according to the combinations described above. However, for practical reasons and to be able to compare the articles within one systematic review, we took into account only the epidemiological studies (toxicology studies and reviews were excluded), and we constructed two categories of publications for pollution and disease (‘air pollution/airborne particles and diabetes’ and ‘air pollution/airborne particles and neurodegenerative diseases’). In addition, two categories for occupational exposure and disease were included in the final appraisal. We ended up with 36 environmental epidemiological studies and only one occupational study (Figure 1).
Figure 1. Flow chart of the literature search.

2.2. Evaluation of the Systematic Review and Quality of the Studies

The internationally recognised GRADE system for the scientific evaluation of the quality of the identified studies was used to appraise the quality of the studies identified []. This system was developed for assessing interventions in health care contexts, and it has also been adapted to epidemiological studies [,]. In our case, an environmental/occupational factor or exposure can replace the clinical intervention []. The GRADE system classifies the quality of evidence as high, moderate, low, and very low and according to GRADE, evidence based on randomised controlled trials begins as ‘high quality’, and observational studies start as ‘low quality’. All of the cohort and case-control studies epidemiological studies identified for this study were observational. A well-designed observational study can be upgraded and provide a quality grading similar to a randomized controlled trial (RCT), and an RCT can be downgraded if certain aspects are missing. GRADE looks at studies individually, but also considers the whole evidence base.
The following aspects of quality were considered in this study []:
  • Representativeness and size of the study sample, as well as the duration of follow-up period. High number of participants, many years of follow-up, no attrition and lost during follow-up and participants that were members of a bigger cohort, could upgrade the quality of the studies.
  • Publication bias or other kinds of bias, such as selection bias, misclassifications, selective reporting, or conflict of interest diminish the quality of a study. The quality may be downgraded if authors presented incomplete or selectively reported the tested hypothesis, compared to their aim and objectives. If there was no declaration of funder and involvement of the funding body in the research or if the authors had indicated a conflict of interest the quality was also downgraded.
  • Potential confounders such as age, sex, physical activity, education level, alcohol intake, smoking status, socioeconomic status (SES) should have been considered. There is a need of an adequate control of confounding and adjustment in the statistical analysis. If more appropriate potential confounders were taken into account, then the quality of the study could be upgraded.
  • For both exposure and outcome assessment, standardized and validated methods were required. Well established methods enable the comparison between studies and as a result they can contribute to higher quality rating.
This systematic review follows the PRISMA guidelines (Appendix A).

3. Results

The available research uses many different methodological designs to explore the associations between environmental or occupational particle exposures and the health-related outcomes. The approaches mostly quantify particle exposures using various measures of environmental pollution, and the outcome measures are quite disparate.

3.1. Air Pollution and Neurodegeneration

The characteristics of all the included studies focused on investigating the relationship between air pollution exposure and dementia are summarized in Table 1 and Table 2. Of these, 10 studies were cohort studies, 4 studies were cross-sectional, 1 case-control, 2 nested case-control studies, and 1 was a time-series analysis. These were all recent studies, conducted after 2008, in North America (US, n = 10, Canada, n = 1), Europe (Germany, n = 3 and UK, n = 1), and Asia (Taiwan, n = 3). For the cohort studies the range of the follow up periods ranged from 5 to 30 years.
Table 1. Details of studies investigating the relationship between exposure to air pollution and cognitive function.
Table 2. Summaries of exposure and dementia-related outcome considered.
Most studies (17 out of 18) examined airborne particulate matter, four studies also included NOx and two studies considered both PM and traffic noise or proximity to a major road. Five studies quantified black carbon (BC) as a measure of PM. Exposure estimates—assessments based on measurement data—were mostly based on data from air monitors at fixed monitoring sites, using either the participant’s postcode [,], address of residence [,,,,], county [] or the community []. Half of the studies (9 out of 18) considered traffic-related air pollution (BC, NOx, NO2, traffic noise, proximity to a major road, traffic PM), and their findings supported an association between air pollution exposure and dementia-related outcomes. Furthermore, one study supported a positive association of mild cognitive impairment (MCI) with road traffic noise [] and a second study supports an association between shorter distance to a very busy road (10,000 cars per day) and poorer performance in a general assessment of cognition and a selective attention test [].
Two studies used neuroimaging to show an adverse association between PM exposure and neurodegeneration (PD and white matter (WM) loss) [,]. One study supported an adverse association between PM and performance on a general ability test (working memory and orientation) [], another supported an adverse association with visuo-spatial ability [], another supported an adverse association with reasoning, short term memory, and verbal fluency []. Other studies identified adverse associations between cognitive decline and performance of mini mental state examination (MMSE) [,] and an adverse association between PM and hospitalization for neurodegenerative diseases []. Four studies found no association between PM exposure and the health outcomes of interest based on examining medical records or participant’s reports [,,,].
There was a wide range of techniques used to assess neurodegeneration and here we discuss the validity of different approaches. There is no single test that can provide a definitive diagnosis of Alzheimer’s or other neurodegenerative disease in life. Diagnosis considers a range of cognitive abilities and functions and there is a need to look at them longitudinally. Physical and neurological examination, mental status tests (cognitive test scores, tests within a battery), neuroimaging, and medical history may all provide an insight into dementia-related endpoints. Information from laboratory tests or a physical examination can help identify health issues that can cause symptoms of dementia. Imaging technologies have revolutionized the understanding of the structure and function of the living brain to better track and diagnose the progress of Alzheimer’s disease. Each method of detecting the dementia-related outcome has advantages and disadvantages. Cognitive test scores are informative and easy to use in epidemiology studies [], whereas using a battery of tests offer considerable advantage over traditional measures (MMSE) “for predicting and discriminating stable from deteriorating forms of suspected dementia at an individual level” []. Furthermore, neuroimaging plays a crucial part in the diagnosis of dementia and provides a perception of the underlying pathologic process. Neuroimaging is important not only to exclude non-AD pathologies, but also to indicate biological markers to support the AD diagnosis [].
Chen and co-workers [] used a neurological examination and imaging to assess cognitive decline and Chen et al. [] included tomography scans as an outcome measure, along with a battery of validated cognitive tests. Tomography scans and especially WM loss measurement is quantitative and specific to identify cognitive decline. Jung and colleagues used both history examination and neuroimaging []. However, most of the studies use a variety of different cognitive tests to measure cognitive decline [,,,,,,,,], medical records [,,], or other self-reports [].
As mentioned above, the size of the study sample, as well as the years of follow-up period were considered in the quality rating and high number of participants, many years of follow-up, and participants that were members of a larger cohort, can upgrade the studies. Kioumourtzoglou et al. [] had the largest sample size, which included 9,817,806 adults, both men and women. The follow up period of the study was about 10 years and the study showed positive associations with all the three outcomes (PD, AD, and dementia). Chen et al. [] had the second largest sample size, which again included men and women, 20–85 years, and had a long follow-up period (12 years). Both studies of Palacios et al. included thousands of participants and had more than 15 years of follow-up. Weuve et al. [] had 19,409 female participants, who were part of the Nurses’ Health Study Cognitive Cohort, and a follow up period of approximately 10 years. Ranft et al. [], which was based on the SALIA cohort, studied proximity to a major road and had a 20 year of follow up period. Jung et al. [] performed a study of 95,690 participants over 10 years, by using history, examination, lab tests and MRI to examine the associations between air pollution exposure and the health outcome. Studies of Kirrane et al., Tonne et al. and Power et al. [,,] had adequate sample size and follow up period of 17 years, 5 years, and 10 years accordingly. Ranft et al. and Power et al. found no association with PM10 and the cross-sectional study of Chen & Schwarts was statistically significant only for O3. The remaining studies are cross-sectional studies of Tzivian et al., Chen & Schwarts, Schikowski et al. and Ailshire & Clarke, with the last study having a lost to follow-up from 1986. There is also one small case control study from Wu et al. comprised of 871 participants and only three years of follow-up. All of the other studies found statistically significant results, as mentioned above, except for three that found no statistically significant associations between particulate air pollution and PD.
Most of the reviewed studies adjusted for age, sex, smoking status, and physical activity, although several studies failed to adjust for sociodemographic factors, such as education or SES, which may potentially be confounders [,,,]. Lower education and low annual income have been associated with a greater risk for dementia [,,] and it is plausible that people with low income live in areas with high levels of pollution. Although it is clear that people with cardiometabolic diseases tend to be more vulnerable to air pollution and that cardiometabolic diseases are a risk factor for cognitive dysfunction, only a few studies adjusted for such conditions [,,,]. Moreover, exposure to high levels of noise impairs cognitive abilities [], and a large fraction of ambient pollution is traffic generated, making noise a possible confounder; only two studies adjusted for environmental noise exposure [,].
Bias, misclassification, and selective reporting can diminish the study quality. From our 18 studies, two mentioned selection bias [,], where people who were cognitively impaired were less likely to participate. Five studies [,,,,] mentioned misclassification of personal exposure levels (exposure misclassification), because the exposures were estimated from residential address, and one study [] mentioned outcome misclassification; the measures of the diseases were based on hospital admission records, with the possibility of misclassification of diagnosis.
Most of the studies do not report a conflict of interest and were funded by a national agency [,,,,,,,,,,,,,,]. However, two publications [,] did not contain any conflict of interest statement.
Taken together, the results from existing epidemiological studies suggest that there is a relationship between PM exposure and cognitive decline.

3.2. Air Pollution and Diabetes (T2DM)

The characteristics of all the epidemiology studies which have assessed the link between PM exposure and T2DM are summarized in Table 3 and Table 4. These mostly comprise cohort studies, except for five cross-sectional studies [,,,,]. They were conducted in North America (Canada, n = 2 and US, n = 6), Europe (UK, n = 1, Switzerland, n = 2, Denmark, n = 1 and Germany, n = 3), and Asia (Korea, n = 1 and China, n = 2). For the cohort studies, the length of the follow up ranged from 3 to 22 years.
Table 3. Details of studies investigating the relationship between exposure to air pollution and diabetes mellitus.
Table 4. Summaries of exposure considered in diabetes studies.
Most studies of environmental exposure (17 out of 18) examined associations with airborne particulate matter, although 12 studies also considered NOx, or traffic noise and proximity to a major road, and two studies considered annual mean residential BC concentration. Exposure estimates were mostly based on air monitors at fixed locations. There was one publication that investigated occupational exposure to environmental pollution, which was amongst traffic police. This study estimated exposure from PM monitors at fixed locations in different areas with various intensities of vehicle traffic [].
A previous comprehensive meta-analysis of 12 studies, which also reviewed the study of Brook et al. [] has shown that ambient PM and exposure to air pollutants, such as NO2 and O3, were significantly associated with an increased risk of diabetes mortality []. Therefore, the findings from this meta-analysis add evidence for the adverse effect of particulate air pollution on diabetes- associated mortality and although diabetes is a risk factor for many other conditions (e.g., cardiovascular disease), this meta-analysis shows what it is already established; that higher levels of air pollutants, such as PM10, PM2.5, and NO2 are associated with T2DM.
There are two studies ([,]) in our review that examined diabetes mortality. Other studies investigated this association by assessing the incidence of T2DM from hospital admissions [], or hospital diagnosis [], or self-reports []. Diabetes status can be measured directly from biomarkers [], such as fasting blood glucose (FBG), but also because insulin resistance (IR) and inflammation are important hallmarks of T2DM, biomarkers of inflammation, such as C-reactive protein (CRP), are also relevant. Most of the studies in this review used questionnaires and interviews, that collected information on treatment, blood glucose measurements, insulin, leptin, HbA1c, and CRP levels [,,,], but some studies carried out only blood tests of the above biomarkers [,,], or used both methods [,,].
In five studies [,,,,] the outcome was measured using both questionnaires, completed by the participants and blood samples taken by them. There were two studies [,] based on hospital admission and diagnosis, four studies [,,,] that relied on samples taken by health specialists and one [] based on a physical examination. Finally, there were three studies [,,] that only used questionnaires, which may result in misclassification because of the use of self-reported diagnosis, and could not identify undiagnosed cases of diabetes.
In terms of study sample size and follow-up, Brook et al. [] had the largest sample size (2.1 million adults) and a 10-year follow-up period. Pope and colleagues [] also had a very large sample size (669,046 adults) and a 22-year follow-up. Puett and co-workers [] had 74,412 participants and Chen et al. [] had 62,012 participants, both with a 14-year follow-up. Five studies [,,,,,,,,] reanalysed data from existing cohorts. Studies of Eze et al., Liu et al., Wolf et al., and O’Donovan et al. [,,,,] are all cross-sectional studies and Liu et al. [] and both O’Donovan et al. [] and Wolf et al. [] had one and three years of follow-up, respectively. All of the studies found statistically significant results, as mentioned above, except for Chen et al. [], who found that exposure to PM10 was associated with an increased level of FBG in the univariable analysis, whereas the results in the multipollutant model were not significant and Puett et al. who found no strong evidence between PM and T2DM.
It is known that an unhealthy diet can lead to obesity, one of the biggest risk factors of diabetes. Moreover, some studies indicate that the effects of PM and NO2 are more noticeable in females []. Almost all the studies adjusted for BMI, sex, age, education, and physical activity. Some also adjusted for family history of diabetes [,]; or genes and genetic predisposition already known as risk factors of T2DM. It is hypothesised from animal studies and limited human subjects’ studies, that air pollutants can decrease the normal synthesis of insulin [], therefore in studies investigating environmental pollution it is important to adjust for occupational exposure to vapours, gases, dusts, and fumes, that are similar to urban air pollutants; only two studies did so [,]. Moreover, exposure to physical agents, such as noise -both indoor and outdoor-, can also modify the levels of the insulin, therefore adjustment for noise could be important, as Eze and colleagues [] did.
All the studies mentioned limitations that can downgrade study quality, particularly information bias. Ten studies mentioned exposure misclassification [,,,,,,,,,] and two outcome misclassification [,], due to self-reporting of diagnosis. Two studies [,] measured the disease outcome from a mortality database and death certificates, possibly underestimating the true prevalence of T2DM. Underestimation of the effect, because of a selected sample of study subjects, was mentioned in two studies [,]. All the studies declared no conflict of interest and were funded by national agencies.
Taken together the results from existing epidemiological studies suggest that there is a relationship between PM exposure and T2DM.

3.3. Rating the Quality of Evidence According to GRADE

GRADE considers quality, publication bias, consistency, directness, and effect size and we discuss each in turn. In this system, observational studies start as low-quality evidence, but they can be rated down in a case of high risk of publication bias. There may be some doubt when the evidence derives from many small studies and especially if these studies have been commercially funded []. The evidence in this review comes from large observational studies and none of the studies was funded by industry. We have found some studies with statistically significant results and other ‘null studies’ of similar size; there is little evidence of publication bias.
In the GRADE scheme, the quality of evidence decreases when essential differences occur between the populations studied, or the outcomes measured, particularly if the outcomes are indirectly related to the disease []. For example, in our systematic review, the population of interest in all the 37 studies was adults, but some studies were conducted in women or men only [,,,,,,,,,], which might influence the generalisability of the reported results, as studies of both sexes do not always examine risks separately for males and female and as the two genders may have different exposures because of different occupations for example, or because, as mentioned above, some effects are more noticeable in women. Also, there is a possibility that the desired outcome may be different from the measured outcome. The use of surrogate endpoints instead of ‘patient-important outcome of interest’ can be a source of indirectness []. For example, in diabetes-related studies the patient-important outcomes may be the hospital admission, diabetic symptoms, or complications because of diabetes and the surrogate outcome measures blood glucose or HbA1c concentration. In our review, there are studies that assess T2DM by looking at hospital admissions [,], or questionnaires [,], but there are also studies that measure the fasting blood glucose and other blood biomarkers [,,,]. In the dementia-related studies, the patient-important outcome may be the patient’s function and behaviour, whereas the surrogate outcomes may be measures of cognitive function. In most of our dementia studies the measurement of the health outcome was cognitive function not a patient-important outcome.
GRADE also examines the consistency of the evidence; are there conflicting results in groups between studies, for example do the majority shows associations, do the studies have similar results, or is there a lack of agreement between studies? Existing evidence from meta-analysis indicates an association between air pollutants and both T2DM [] and cognitive decline []. The studies that examined neurodegeneration-related outcomes mostly reported positive associations of particulate air pollution exposure and only three studies found no association [,,]. We judge there is convincing evidence for consistency in the association of particulate ambient air pollution, cognitive decline, and dementia (AD), although there are conflicting results for an association between air pollution and PD. More specifically, seven studies indicated associations between fine particulate and traffic related air pollution and cognitive decline and impairment [,,,,,,], two studies identified association between air pollution and AD and dementia [,], two studies evaluated the association between air pollution exposure and only PD positively [,] and one study used a time-series-like approach to link particulate matter pollution with both PD, AD, and dementia []. Generally, a causal role of particulate matter can be concluded from many studies and also traffic emissions and living near busy roads can be a health threat. Increased daily levels of air pollution are related to higher hospital admissions and adverse health conditions [,].
Exposure to air pollution has already been suggested as a contributing factor to the increasing incidence and prevalence of diabetes [,] and all of the diabetes-related studies but one [], reported positive associations between particulate air pollution exposure and diabetes-related outcomes.
It is also important to look at the effect of all possible confounding factors. In our systematic review, not all the possible confounders have been accounted for. In some cases, it is hard to exclude the possibility of social confounders. Moreover, most of the studies do not address indoor sources of air pollution, which cannot be calculated using geospatial models of air pollutants, therefore personal monitoring should take place at future studies to give us a clearer picture of the impact of different sources of pollutants. Another potential confounding variable that should be better explored in future studies is noise pollution, because of the possible association with memory loss.
Effect size, according to the GRADE approach, is based on the reported odds ratio, or relative risk or hazard ratio (OR/RR/HR) for comparison. However, it is somewhat unreliable to assess the odds ratios, due to different methodological approaches in the studies, but for most studies the observed risks were all modestly increased. There are no studies with an RR or OR of 2 or more, although most of them were statistically significant (except for [,,]).
The GRADE evidence is discussed further in the following section.

4. Discussion

T2DM and dementia are common multi-causal conditions. An unhealthy diet, obesity, stress, culture, physical inactivity, and genetic predisposition may lead to cardio-metabolic diseases, such as T2DM []. Furthermore, both environmental and genetic factors play a crucial role in the aetiology of neurodegenerative diseases (e.g., AD) [], depression, delirium, stroke, traumatic brain injury, ageing, and family history []. There are some familial cases (that are associated with genetic abnormalities) and some environmental factors have been identified as risk factors for neurological disease (e.g., pesticide exposure), but most of these cases are idiopathic [].
Epidemiological evidence suggests that long term exposure to particulate air pollution is a risk factor for T2DM and dementia. The mechanism underlying this is currently unknown, but it may involve the translocation of inhaled particles to the target site (e.g., CNS), or the release of (inflammatory) mediators from the lung which impact on the function of extrapulmonary organs [,,] (Figure 2). In the lung, it is established that PM stimulates inflammatory and oxidative responses, which drive its toxicity (reviewed in [,,]). Accordingly, both these processes are likely to be important in mediating the detrimental outcomes of PM in other organs.
Figure 2. Following inhalation, particles may stimulate local or systemic effects. The hypothesised mechanism of toxicity of inhaled particles to the central nervous system (CNS) is summarized in (A). Impacts of inhaled particles on the CNS may emerge due to (i) particle translocation (via neurones or blood) to the CNS following inhalation or (ii) the release of systemically acting factors from the lung which impact on neurone function. Examples of the clinical impacts of inhaled particles at different target sites (lung, extrapulmonary organs, and CNS) are summarised in blue boxes; (B) The cellular and molecular events underlying particle toxicity to the lungs have been extensively investigated and hypothesised to involve the stimulation of inflammation and oxidative stress. More specifically, it is hypothesized that inhaled ultrafine particles interact with pulmonary cells (e.g., epithelial cells, alveolar macrophages) to stimulate an increase in intracellular ROS and Ca2+ concentration which leads to the expression of pro-inflammatory genes (e.g., cytokines) via the activation of transcription factors (such as NFκB). BBB = blood brain barrier. COPD = chronic obstructive pulmonary disease.
More specifically, inflammation and oxidative stress are implicated in the pathogenesis of neurodegenerative diseases and T2DM. Therefore, exposure to PM may contribute to the initiation of disease pathogenesis or accelerate disease development potentiating existing responses.
Chronic inflammation has been found to be associated with the development of T2DM in humans []. Furthermore, a chronic inflammatory response is associated with obesity [], one of the main risk factors for T2DM. Insulin resistance (IR) is one of the most important hallmarks in the pathogenesis of T2DM. IR is directly linked with a variety of inflammatory responses and these responses play a crucial role in the development of the condition []. Indeed, quantification of inflammatory mediators in blood is used as a biomarker for T2DM []. Individuals with T2DM have elevated cytokine levels in blood compared to people without diabetes and there is mounting evidence that supports that diabetes and particulate air pollution are associated with inflammatory dysregulation [,,]. In addition, there is evidence that increased exposure to PM is significantly associated with increased fasting blood glucose (a biomarker for diabetes) in humans [,]. Whilst epidemiological evidence suggests that PM exposure is a risk factor for T2DM development, further research is required to better understand the cellular and molecular events underlying this as few studies have investigated the mechanism of toxicity, to date.
Numerous studies have established the role of neuroinflammation in both AD and PD pathology [,]. When inflammation is activated, neurones, and microglia cells release pro-inflammatory mediators (e.g., cytokines) which can stimulate an inflammatory response which damages neuronal cells and ultimately brain tissue [,]. The stimulation of inflammation is key to the pathogenesis of dementia. For example, the degree of inflammation correlates with brain atrophy and the severity of dementia in early AD []. There are also markers of inflammation, such as C-reactive protein levels (CRP) and interleukin-6 (IL-6) that are elevated in the blood plasma of patients with AD and vascular dementia []. An increase in the levels of the inflammatory markers in blood is associated with an increase in the risk of all types of dementia []. Moreover, it is already known that higher levels of inflammatory markers are associated with greater brain atrophy than expected for age [].
Exposure to particulate air pollution, has been linked also with brain inflammation []. The first indications that inhaling polluted air could cause neurodegeneration came from an experiment with demented dogs in Mexico City. In this experiment, canines were exposed to significant concentrations of ozone, PM, and other pollutants. The researchers identified inflammation in the brains of the dogs along with endothelial damage, which prompted the hypothesis that the initial inflammatory source was the respiratory tract []. There is now evidence from several in vivo studies that PM can stimulate inflammatory and oxidative responses in the CNS [,,,,,,]. Furthermore, Hullmann et al. [] demonstrated that diesel exhaust particles accelerated the development of hallmarks of Alzheimer’s Disease in a mouse disease model. In addition, Finch and Morgan [] showed in mice that inhalation of particulate polluted air activated the brain’s microglia, which stimulated an inflammatory response that was linked to memory loss and the pollution-exposed mice showed signs of brain damage. They suggested that the fine airborne particles might travel from the nasal cavity to the brain. Interestingly, few in vitro studies [,,,,] have investigated the response of neurones to PM10 despite evidence from epidemiology and in vivo studies that PM10 can cause neurotoxicity.
Exposure to environmental toxicants (such as air pollutants) increases the risk of Parkinson’s disease [] and there is evidence that neuroinflammation is the etiopathogenesis not only for Alzheimer’s disease, but also of Parkinson’s disease [,]. Long-term exposure to particulate air pollution may cause damage to dopaminergic neurons and lead to chronic brain inflammation to accelerate AD and PD development [].
Epidemiological evidence has identified that diabetes and neurodegenerative diseases are linked, for example it is known that people with a metabolic syndrome, such as diabetes, are at higher risk of developing cognitive impairment [] and Alzheimer’s disease. IR links obesity with pre-diabetes and diabetes and is associated with an increased risk for cognitive decline [] and age-related memory impairment and AD []. Metabolic syndrome is considered as an independent risk factor for pre-AD syndrome and AD [,,,] and generally diabetes is a known risk factor for cognitive dysfunction and all-cause dementia []. T2DM is similar to AD in many ways. They are both associated with impaired glucose uptake, increased oxidative stress, inflammation, ageing, brain atrophy and they may both cause impaired cognition and dementia. This suggests that these two diseases share many factors in terms of pathophysiology and clinical outcome and due to the similarity and the pathophysiological bridge between them, AD is often referred as “type 3 diabetes” [,]. There is also a link between diabetes and Parkinson’s disease []. Individuals with T2DM are at increased risk of developing PD [,].
The relationship between diabetes and neurodegenerative disease may arise as a consequence of a common inflammatory mechanism []. For example, among individuals with metabolic syndrome, those with a higher level of inflammation are at higher risk of developing cognitive impairment compared to those with low inflammation []. Whilst there is evidence that inflammation is linked to both T2DM and neurodegenerative diseases, it is uncertain whether T2DM is a prerequisite to develop neurodegenerative disease from this inflammatory mechanism, or whether inflammatory processes act independently to cause these diseases. Furthermore, the hormone insulin plays an important role in memory and in brain function [] and thus dysregulation of insulin signalling has been linked to metabolic and neurodegenerative disorders [,]. Accordingly, several conditions, including T2DM, activate a range of inflammatory, metabolic, and oxidative changes that might contribute to deleterious effects on the brain and other metabolic changes that might potentially drive neurodegenerative processes [].
In this systematic review, we considered 37 studies and both levels and assessment of exposure and outcome definitions varied. The majority of the studies (31 out of 37) indicated a positive association between particulate traffic-related air pollution and cognitive impairment and/or T2DM. However, the quality of the epidemiological evidence is considered ‘poor’ because of the observational nature of the studies and there are not RCT studies that would increase the quality of the evidence. The quality of the evidence base is also poor either because it is often based on self-reports rather than on objective cognitive tests, clinical examination or neuroimaging. Furthermore, diabetes-related studies that were based on mortality data, could have underestimated the true prevalence of the disease.
Noise exposure is closely correlated with traffic related air pollution, and noise exposure is an independent risk factor for neurodegenerative diseases [,]. Moreover, when investigating noise or traffic proximity, which is an indicator of traffic noise, it is important to consider hearing impairment with ageing in the adult population. It is important that epidemiological studies adjust for noise exposure, although the majority of existing studies did not. It is also important that studies consider established risk factors of the disease such as obesity, nutrition, and active and passive smoking. The majority of the studies adjusted for smoking status, but only few adjusted for certain food consumption; such as fish consumption, which is associated with the risk for dementia []. A healthy survivor effect may also be important in some studies, because with ageing, some diabetes or dementia patients could die prematurely and no longer participate. Other lifestyle factors or other health status covariates should also be considered, such as activities of everyday life—i.e., computer experience or depression symptoms—because they play a crucial role in cognitive performance and only few studies considered them. Lack of information on these could lead to a risk of bias. Moreover, family history of cardiovascular disease can also be important and should be considered, but some studies only mentioned cardiovascular risk factors or already existing cardiovascular disease.
We were not able to perform a meta-analysis because of the variety of different outcomes that were described in the studies. However, previous review studies on T2DM have done meta-analysis for different exposure subgroups and all support an association of air pollutants with an increased risk for T2DM [,,]. In practice a meta-analysis would be feasible with any of the morbidity or mortality endpoints provided there were sufficient contributing studies with consistency in the definition of the outcomes.
There are many occupations that are exposed to airborne particles, but there is only one epidemiological study that is informative about possible risks of T2DM and dementia from such exposure []. In workplaces, ultrafine particles are found in metal and polymer fumes and both can induce acute inflammation responses in the lung upon inhalation []. Many other occupational aerosol exposures can cause chronic lung inflammation—some closely related to air pollution, such as diesel engine exhaust particulate and others, such as respirable crystalline silica, that cause inflammation because of chemical or surface properties. Carbon black workers may show lung function reduction along with pro-inflammatory cytokines secretion []; exposure to dust can cause pulmonary reactions in dairy farmers, cotton workers, and wood workers; and inhalation of irritants can demonstrate pulmonary inflammation []. Also ultrafine particles can affect the nasal epithelium and produce inflammation that damages the brain [].
As we have seen, inflammation is the key biological process linked to T2DM and neurodegeneration. By analogy, we judge that occupational particulate exposure that causes inflammation is a ‘possible’ cause of T2DM and neurodegenerative diseases due to the relatively high exposures that are likely to occur in the work environment. However, further research is needed to clarify whether there is a risk from workplace particulate exposures.

5. Conclusions

Despite the various studies investigating the association between air pollution and T2DM and cognitive impairment and neurodegeneration, the role of air pollution in the causation of these disorders is not fully understood and remains unclear. Available evidence indicates a positive association of ambient particulate air pollution and both T2DM and neurodegeneration risk, but corresponding evidence for similar workplace exposures is lacking. However, it is plausible that such an association between fine aerosols in the workplace are associated these diseases. Further research is required to identify the link and toxicological mechanisms associated with particulate exposure and T2DM and neurodegenerative disease. Future studies could fill key evidentiary gaps and thereby lead to additional steps to decrease air pollution levels and improve policies in the workplace environment to decrease the incidence of T2DM and cognitive decline, creating a healthier and more sustainable future.

Author Contributions

E.D. served as the primary author performing initial database searches and drafting the initial manuscript. J.W.C. also performed initial database search. J.W.C. conceived the review and was the research supervisor, assisting with database searching, quality appraisal and providing critical feedback and is the corresponding author. G.S. and H.J.J. provided guidance and critical feedback and editing on the manuscript. All authors read and approved the final manuscript for submission.

Funding

E.D. thanks the Colt Foundation for financial support through a personal fellowship.

Acknowledgments

E.D. acknowledges the feedback provided by Damien McElvenny (IOM, Edinburgh).

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Table A1. PRISMA checklist.
Table A1. PRISMA checklist.
Section/Topic#Checklist ItemReported on Page #
TITLE
Title1Identify the report as a systematic review, meta-analysis, or both.1
ABSTRACT
Structured summary2Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.1
INTRODUCTION
Rationale3Describe the rationale for the review in the context of what is already known.1–2
Objectives4Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).1–2
METHODS
Protocol and registration5Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.-
Eligibility criteria6Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.3
Information sources7Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.3
Search8Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.3
Study selection9State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).3
Data collection process10Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.3
Data items11List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.8–25
Risk of bias in individual studies12Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.4–5
Summary measures13State the principal summary measures (e.g., risk ratio, difference in means).8–15, 17–24
Synthesis of results14Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.4–5
Risk of bias across studies15Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).5, 7, 8–15, 17–24, 26
Additional analyses16Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.-
RESULTS
Study selection17Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.4
Study characteristics18For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.8–25
Risk of bias within studies19Present data on risk of bias of each study and, if available, any outcome level assessment (see Item 12).8–15, 17–24
Results of individual studies20For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.8–15, 17–24
Synthesis of results21Present results of each meta-analysis done, including confidence intervals and measures of consistency.-
Risk of bias across studies22Present results of any assessment of risk of bias across studies (see Item 15).7, 26
Additional analysis23Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression (see Item 16)).-
DISCUSSION
Summary of evidence24Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).8–25, 30
Limitations25Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).30
Conclusions26Provide a general interpretation of the results in the context of other evidence, and implications for future research.31
FUNDING
Funding27Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.31

References

  1. Nenonen, N.; Saarela, K.L.; Takala, J.; Hamalainen, P. Global Estimates of Occupational Accidents and Fatal Work-Related Diseases; International Labour Office (ILO): Frankfurt, Germany, 2014; pp. 1–26. [Google Scholar]
  2. Health and Safety Executive. Health and Safety Statistics for UK Report; Health and Safety Executive: Bootle, UK, 2016.
  3. World Health Organization (WHO). Ambient Air Pollution: A Global Assessment of Exposure and Burden of Disease; WHO: Geneva, Switzerland, 2016. [Google Scholar]
  4. WHO. Global Health Risks: Mortality and Burden of Diseases Attributable to Selected Major Risks; WHO: Geneva, Switzerland, 2009. [Google Scholar]
  5. Every Breath We Take: The Lifelong Impact of Air Pollution; Royal College of Physicians: London, UK, 2016.
  6. Donaldson, K.; Seaton, A. A short history of the toxicology of inhaled particles. Part. Fibre Toxicol. 2012, 9, 13. [Google Scholar] [CrossRef] [PubMed]
  7. Jun, K. Case Study of Air Pollution Episodes in Meuse Valley of Belgium, Donora of Pennsylvania, and London, UK. In Environmental Toxicology and Human Health; Satoh, T., Ed.; Eolss Publishers Co. Ltd.: Oxford, UK, 2009; Volume I. [Google Scholar]
  8. Seaton, A.; MacNee, W.; Donaldson, K.; Godden, D. Particulate air pollution and acute health effects. Lancet 1995, 345, 176–178. [Google Scholar] [CrossRef]
  9. Donaldson, K.; Stone, V. Current hypotheses on the mechanisms of toxicity of ultrafine particles. Annali Dell’istituto Superiore di Sanita 2003, 39, 405–410. [Google Scholar] [PubMed]
  10. Stone, V.; Miller, M.R.; Clift, M.J.D.; Elder, A.; Mills, N.L.; Moller, P.; Schins, R.P.F.; Vogel, U.; Kreyling, W.G.; Alstrup Jensen, K.; et al. Nanomaterials Versus Ambient Ultrafine Particles: An Opportunity to Exchange Toxicology Knowledge. Environ. Health Perspect. 2017, 125, 106002. [Google Scholar] [CrossRef] [PubMed]
  11. Brook, R.D.; Rajagopalan, S.; Pope, C.A., 3rd; Brook, J.R.; Bhatnagar, A.; Diez-Roux, A.V.; Holguin, F.; Hong, Y.; Luepker, R.V.; Mittleman, M.A.; et al. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation 2010, 121, 2331–2378. [Google Scholar] [CrossRef] [PubMed]
  12. Dockery, D.W.; Pope, C.A., 3rd; Xu, X.; Spengler, J.D.; Ware, J.H.; Fay, M.E.; Ferris, B.G., Jr.; Speizer, F.E. An association between air pollution and mortality in six U.S. cities. N. Engl. J. Med. 1993, 329, 1753–1759. [Google Scholar] [CrossRef] [PubMed]
  13. Schwartz, J. Air pollution and daily mortality: A review and meta analysis. Environ. Res. 1994, 64, 36–52. [Google Scholar] [CrossRef] [PubMed]
  14. D’Amato, G. Outdoor air pollution in urban areas and allergic respiratory diseases. Monaldi Arch. Chest Dis. 1999, 54, 470–474. [Google Scholar] [PubMed]
  15. Jovanovic-Andersen, Z. Health effects of long-term exposure to air pollution: An overview of major respiratory and cardiovascular diseases and diabetes. Chem. Ind. Chem. Eng. Quart. 2012, 18, 617–622. [Google Scholar] [CrossRef]
  16. WHO. Air Pollution and Cancer; WHO: Geneva, Switzerland, 2013. [Google Scholar]
  17. Eze, I.C.; Schaffner, E.; Fischer, E.; Schikowski, T.; Adam, M.; Imboden, M.; Tsai, M.; Carballo, D.; von Eckardstein, A.; Kunzli, N.; et al. Long-term air pollution exposure and diabetes in a population-based Swiss cohort. Environ. Int. 2014, 70, 95–105. [Google Scholar] [CrossRef] [PubMed]
  18. Wang, B.; Xu, D.; Jing, Z.; Liu, D.; Yan, S.; Wang, Y. Effect of long-term exposure to air pollution on type 2 diabetes mellitus risk: A systemic review and meta-analysis of cohort studies. Eur. J. Endocrinol. 2014, 171, R173–R182. [Google Scholar] [CrossRef] [PubMed]
  19. Teichert, T.; Vossoughi, M.; Vierkotter, A.; Sugiri, D.; Schikowski, T.; Schulte, T.; Roden, M.; Luckhaus, C.; Herder, C.; Kramer, U. Association between traffic-related air pollution, subclinical inflammation and impaired glucose metabolism: Results from the SALIA study. PLoS ONE 2013, 8, e83042. [Google Scholar] [CrossRef] [PubMed]
  20. Coogan, P.F.; White, L.F.; Jerrett, M.; Brook, R.D.; Su, J.G.; Seto, E.; Burnett, R.; Palmer, J.R.; Rosenberg, L. Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles. Circulation 2012, 125, 767–772. [Google Scholar] [CrossRef] [PubMed]
  21. De Jager, C.; Blackwell, A.; Budge, M.; Sahakian, B. Predicting cognitive decline in healthy adults. Am. J. Geriatr. Psychiatry 2005, 13, 735–740. [Google Scholar] [CrossRef] [PubMed]
  22. Liu, C.; Bai, Y.; Xu, X.; Sun, L.; Wang, A.; Wang, T.Y.; Maurya, S.K.; Periasamy, M.; Morishita, M.; Harkema, J.; et al. Exaggerated effects of particulate matter air pollution in genetic type II diabetes mellitus. Part. Fibre Toxicol. 2014, 11, 27. [Google Scholar] [CrossRef] [PubMed]
  23. Dubowsky, S.D.; Suh, H.; Schwartz, J.; Coull, B.A.; Gold, D.R. Diabetes, Obesity, and Hypertension May Enhance Associations between Air Pollution and Markers of Systemic Inflammation. Environ. Health Perspect. 2006, 114, 992–998. [Google Scholar] [CrossRef] [PubMed]
  24. Weinmayr, G.; Hennig, F.; Fuks, K.; Nonnemacher, M.; Jakobs, H.; Mohlenkamp, S.; Erbel, R.; Jockel, K.H.; Hoffmann, B.; Moebus, S.; et al. Long-term exposure to fine particulate matter and incidence of type 2 diabetes mellitus in a cohort study: Effects of total and traffic-specific air pollution. Environ. Health 2015, 14, 53. [Google Scholar] [CrossRef] [PubMed]
  25. Rajagopalan, S.; Brook, R.D. Air pollution and type 2 diabetes: Mechanistic insights. Diabetes 2012, 61, 3037–3045. [Google Scholar] [CrossRef] [PubMed]
  26. Jung, C.R.; Lin, Y.T.; Hwang, B.F. Ozone, particulate matter, and newly diagnosed Alzheimer’s disease: A population-based cohort study in Taiwan. J. Alzheimer’s Dis. 2015, 44, 573–584. [Google Scholar] [CrossRef] [PubMed]
  27. Moulton, P.V.; Yang, W. Air pollution, oxidative stress, and Alzheimer’s disease. J. Environ. Public Health 2012, 2012, 472751. [Google Scholar] [CrossRef] [PubMed]
  28. Calderon-Garciduenas, L.; Franco-Lira, M.; Mora-Tiscareno, A.; Medina-Cortina, H.; Torres-Jardon, R.; Kavanaugh, M. Early Alzheimer’s and Parkinson’s disease pathology in urban children: Friend versus Foe responses—It is time to face the evidence. BioMed Res. Int. 2013, 2013, 161687. [Google Scholar] [CrossRef] [PubMed]
  29. Kirrane, E.F.; Bowman, C.; Davis, J.A.; Hoppin, J.A.; Blair, A.; Chen, H.; Patel, M.M.; Sandler, D.P.; Tanner, C.M.; Vinikoor-Imler, L.; et al. Associations of Ozone and PM2.5 Concentrations With Parkinson’s Disease Among Participants in the Agricultural Health Study. J. Occup. Environ. Med. 2015, 57, 509–517. [Google Scholar] [CrossRef] [PubMed]
  30. Heusinkveld, H.J.; Wahle, T.; Campbell, A.; Westerink, R.H.S.; Tran, L.; Johnston, H.; Stone, V.; Cassee, F.R.; Schins, R.P.F. Neurodegenerative and neurological disorders by small inhaled particles. Neurotoxicology 2016, 56, 94–106. [Google Scholar] [CrossRef] [PubMed]
  31. Oberdorster, G.; Sharp, Z.; Atudorei, V.; Elder, A.; Gelein, R.; Kreyling, W.; Cox, C. Translocation of inhaled ultrafine particles to the brain. Inhal. Toxicol. 2004, 16, 437–445. [Google Scholar] [CrossRef] [PubMed]
  32. Park, S.K.; Adar, S.D.; O’Neill, M.S.; Auchincloss, A.H.; Szpiro, A.; Bertoni, A.G.; Navas-Acien, A.; Kaufman, J.D.; Diez-Roux, A.V. Long-Term Exposure to Air Pollution and Type 2 Diabetes Mellitus in a Multiethnic Cohort. Am. J. Epidemiol. 2015, 181, 327–336. [Google Scholar] [CrossRef] [PubMed]
  33. Guyatt, G.H.; Oxman, A.D.; Vist, G.E.; Kunz, R.; Falck-Ytter, Y.; Alonso-Coello, P.; Schunemann, H.J.; Group, G.W. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336, 924–926. [Google Scholar] [CrossRef] [PubMed]
  34. Theorell, T.; Hammarstrom, A.; Aronsson, G.; Traskman Bendz, L.; Grape, T.; Hogstedt, C.; Marteinsdottir, I.; Skoog, I.; Hall, C. A systematic review including meta-analysis of work environment and depressive symptoms. BMC Public Health 2015, 15, 738. [Google Scholar] [CrossRef] [PubMed]
  35. Morgan, R.L.; Thayer, K.A.; Bero, L.; Bruce, N.; Falck-Ytter, Y.; Ghersi, D.; Guyatt, G.; Hooijmans, C.; Langendam, M.; Mandrioli, D.; et al. GRADE: Assessing the quality of evidence in environmental and occupational health. Environ. Int. 2016, 92–93, 611–616. [Google Scholar] [CrossRef] [PubMed]
  36. Rooney, A.A.; Cooper, G.S.; Jahnke, G.D.; Lam, J.; Morgan, R.L.; Boyles, A.L.; Ratcliffe, J.M.; Kraft, A.D.; Schunemann, H.J.; Schwingl, P.; et al. How credible are the study results? Evaluating and applying internal validity tools to literature-based assessments of environmental health hazards. Environ. Int. 2016, 92–93, 617–629. [Google Scholar] [CrossRef] [PubMed]
  37. Tonne, C.; Elbaz, A.; Beevers, S.; Singh-Manoux, A. Traffic-related air pollution in relation to cognitive function in older adults. Epidemiology 2014, 25, 674–681. [Google Scholar] [CrossRef] [PubMed]
  38. Chen, J.C.; Wang, X.; Wellenius, G.A.; Serre, M.L.; Driscoll, I.; Casanova, R.; McArdle, J.J.; Manson, J.E.; Chui, H.C.; Espeland, M.A. Ambient air pollution and neurotoxicity on brain structure: Evidence from women’s health initiative memory study. Ann. Neurol. 2015, 78, 466–476. [Google Scholar] [CrossRef] [PubMed]
  39. Power, M.C.; Weisskopf, M.G.; Alexeeff, S.E.; Coull, B.A.; Spiro, A., 3rd; Schwartz, J. Traffic-related air pollution and cognitive function in a cohort of older men. Environ. Health Perspect. 2011, 119, 682–687. [Google Scholar] [CrossRef] [PubMed]
  40. Ranft, U.; Schikowski, T.; Sugiri, D.; Krutmann, J.; Kramer, U. Long-term exposure to traffic-related particulate matter impairs cognitive function in the elderly. Environ. Res. 2009, 109, 1004–1011. [Google Scholar] [CrossRef] [PubMed]
  41. Schikowski, T.; Vossoughi, M.; Vierkotter, A.; Schulte, T.; Teichert, T.; Sugiri, D.; Fehsel, K.; Tzivian, L.; Bae, I.S.; Ranft, U.; et al. Association of air pollution with cognitive functions and its modification by APOE gene variants in elderly women. Environ. Res. 2015, 142, 10–16. [Google Scholar] [CrossRef] [PubMed]
  42. Weuve, J.; Puett, R.C.; Schwartz, J.; Yanosky, J.D.; Laden, F.; Grodstein, F. Exposure to particulate air pollution and cognitive decline in older women. Arch. Intern. Med. 2012, 172, 219–227. [Google Scholar] [CrossRef] [PubMed]
  43. Chen, J.C.; Schwartz, J. Neurobehavioral effects of ambient air pollution on cognitive performance in US adults. Neurotoxicology 2009, 30, 231–239. [Google Scholar] [CrossRef] [PubMed]
  44. Kioumourtzoglou, M.A.; Schwartz, J.D.; Weisskopf, M.G.; Melly, S.J.; Wang, Y.; Dominici, F.; Zanobetti, A. Long-term PM2.5 Exposure and Neurological Hospital Admissions in the Northeastern United States. Environ. Health Perspect. 2016, 124, 23–29. [Google Scholar] [CrossRef] [PubMed]
  45. Tzivian, L.; Dlugaj, M.; Winkler, A.; Weinmayr, G.; Hennig, F.; Fuks, K.B.; Vossoughi, M.; Schikowski, T.; Weimar, C.; Erbel, R.; et al. Long-term air pollution and traffic noise exposures and mild cognitive impairment in older adults: A cross-sectional analysis of the Heinz Nixdorf recall study. Environ. Health Perspect. 2016, 124, 1361–1368. [Google Scholar] [CrossRef] [PubMed]
  46. Chen, C.Y.; Hung, H.J.; Chang, K.H.; Hsu, C.Y.; Muo, C.H.; Tsai, C.H.; Wu, T.N. Long-term exposure to air pollution and the incidence of Parkinson’s disease: A nested case-control study. PLoS ONE 2017, 12, e0182834. [Google Scholar] [CrossRef] [PubMed]
  47. Ailshire, J.A.; Clarke, P. Fine particulate matter air pollution and cognitive function among U.S. older adults. J. Gerontol. B Psychol. Sci. Soc. Sci. 2015, 70, 322–328. [Google Scholar] [CrossRef] [PubMed]
  48. Wu, Y.C.; Lin, Y.C.; Yu, H.L.; Chen, J.H.; Chen, T.F.; Sun, Y.; Wen, L.L.; Yip, P.K.; Chu, Y.M.; Chen, Y.C. Association between air pollutants and dementia risk in the elderly. Alzheimer’s Dement. 2015, 1, 220–228. [Google Scholar] [CrossRef] [PubMed]
  49. Palacios, N.; Fitzgerald, K.C.; Hart, J.E.; Weisskopf, M.; Schwarzschild, M.A.; Ascherio, A.; Laden, F. Air Pollution and Risk of Parkinson’s Disease in a Large Prospective Study of Men. Environ. Health Perspect. 2017, 125, 087011. [Google Scholar] [CrossRef] [PubMed]
  50. Palacios, N.; Fitzgerald, K.C.; Hart, J.E.; Weisskopf, M.G.; Schwarzschild, M.A.; Ascherio, A.; Laden, F. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environ. Health 2014, 13, 80. [Google Scholar] [CrossRef] [PubMed]
  51. Liu, R.; Young, M.T.; Chen, J.C.; Kaufman, J.D.; Chen, H. Ambient Air Pollution Exposures and Risk of Parkinson Disease. Environ. Health Perspect. 2016, 124, 1759–1765. [Google Scholar] [CrossRef] [PubMed]
  52. Power, M.C.; Adar, S.D.; Yanosky, J.D.; Weuve, J. Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: A systematic review of epidemiologic research. Neurotoxicology 2016, 56, 235–253. [Google Scholar] [CrossRef] [PubMed]
  53. Ferreira, L.K.; Busatto, G.F. Neuroimaging in Alzheimer’s disease: Current role in clinical practice and potential future applications. Clinics 2011, 66 (Suppl. 1), 19–24. [Google Scholar] [CrossRef]
  54. Chen, H.; Kwong, J.C.; Copes, R.; Tu, K.; Villeneuve, P.J.; van Donkelaar, A.; Hystad, P.; Martin, R.V.; Murray, B.J.; Jessiman, B.; et al. Living near major roads and the incidence of dementia, Parkinson’s disease, and multiple sclerosis: A population-based cohort study. Lancet 2017, 389, 718–726. [Google Scholar] [CrossRef]
  55. Sharp, E.S.; Gatz, M. Relationship between education and dementia: An updated systematic review. Alzheimer Dis. Assoc. Disord. 2011, 25, 289–304. [Google Scholar] [CrossRef] [PubMed]
  56. Fischer, C.; Yeung, E.; Hansen, T.; Gibbons, S.; Fornazzari, L.; Ringer, L.; Schweizer, T.A. Impact of socioeconomic status on the prevalence of dementia in an inner city memory disorders clinic. Int. Psychogeriatr. 2009, 21, 1096–1104. [Google Scholar] [CrossRef] [PubMed]
  57. Russ, T.C.; Stamatakis, E.; Hamer, M.; Starr, J.M.; Kivimaki, M.; Batty, G.D. Socioeconomic status as a risk factor for dementia death: Individual participant meta-analysis of 86,508 men and women from the UK. Br. J. Psychiatry 2013, 203, 10–17. [Google Scholar] [CrossRef] [PubMed]
  58. Liu, C.; Yang, C.; Zhao, Y.; Ma, Z.; Bi, J.; Liu, Y.; Meng, X.; Wang, Y.; Cai, J.; Chen, R.; et al. Associations between long-term exposure to ambient particulate air pollution and type 2 diabetes prevalence, blood glucose and glycosylated hemoglobin levels in China. Environ. Int. 2016, 92–93, 416–421. [Google Scholar] [CrossRef] [PubMed]
  59. Wolf, K.; Popp, A.; Schneider, A.; Breitner, S.; Hampel, R.; Rathmann, W.; Herder, C.; Roden, M.; Koenig, W.; Meisinger, C.; et al. Association Between Long-term Exposure to Air Pollution and Biomarkers Related to Insulin Resistance, Subclinical Inflammation, and Adipokines. Diabetes 2016, 65, 3314–3326. [Google Scholar] [CrossRef] [PubMed]
  60. Eze, I.C.; Schaffner, E.; Foraster, M.; Imboden, M.; von Eckardstein, A.; Gerbase, M.W.; Rothe, T.; Rochat, T.; Kunzli, N.; Schindler, C.; et al. Long-Term Exposure to Ambient Air Pollution and Metabolic Syndrome in Adults. PLoS ONE 2015, 10, e0130337. [Google Scholar] [CrossRef] [PubMed]
  61. O’Donovan, G.; Chudasama, Y.; Grocock, S.; Leigh, R.; Dalton, A.M.; Gray, L.J.; Yates, T.; Edwardson, C.; Hill, S.; Henson, J.; et al. The association between air pollution and type 2 diabetes in a large cross-sectional study in Leicester: The CHAMPIONS Study. Environ. Int. 2017, 104, 41–47. [Google Scholar] [CrossRef] [PubMed]
  62. De Sio, S.; Rosati, M.V.; Cherubini, E.; Ciarrocca, M.; Baccolo, T.P.; Grimaldi, F.; Caciari, T.; Tomao, E.; Tomei, F. Occupational exposure to urban pollutants and plasma insulin. Saudi Med. J. 2005, 26, 416–420. [Google Scholar] [PubMed]
  63. Brook, R.D.; Cakmak, S.; Turner, M.C.; Brook, J.R.; Crouse, D.L.; Peters, P.A.; van Donkelaar, A.; Villeneuve, P.J.; Brion, O.; Jerrett, M.; et al. Long-term fine particulate matter exposure and mortality from diabetes in Canada. Diabetes Care 2013, 36, 3313–3320. [Google Scholar] [CrossRef] [PubMed]
  64. Li, C.; Fang, D.; Xu, D.; Wang, B.; Zhao, S.; Yan, S.; Wang, Y. Main air pollutants and diabetes-associated mortality: A systematic review and meta-analysis. Eur. J. Endocrinol. 2014, 171, R183–R190. [Google Scholar] [CrossRef] [PubMed]
  65. Pope, C.A., 3rd; Turner, M.C.; Burnett, R.T.; Jerrett, M.; Gapstur, S.M.; Diver, W.R.; Krewski, D.; Brook, R.D. Relationships between fine particulate air pollution, cardiometabolic disorders, and cardiovascular mortality. Circ. Res. 2015, 116, 108–115. [Google Scholar] [CrossRef] [PubMed]
  66. Chen, H.; Burnett, R.T.; Kwong, J.C.; Villeneuve, P.J.; Goldberg, M.S.; Brook, R.D.; van Donkelaar, A.; Jerrett, M.; Martin, R.V.; Brook, J.R.; et al. Risk of incident diabetes in relation to long-term exposure to fine particulate matter in Ontario, Canada. Environ. Health Perspect. 2013, 121, 804–810. [Google Scholar] [CrossRef] [PubMed]
  67. Hansen, A.B.; Ravnskjaer, L.; Loft, S.; Andersen, K.K.; Brauner, E.V.; Baastrup, R.; Yao, C.; Ketzel, M.; Becker, T.; Brandt, J.; et al. Long-term exposure to fine particulate matter and incidence of diabetes in the Danish Nurse Cohort. Environ. Int. 2016, 91, 243–250. [Google Scholar] [CrossRef] [PubMed]
  68. Lyons, T.J.; Basu, A. Biomarkers in diabetes: Hemoglobin A1c, vascular and tissue markers. Transl. Res. 2012, 159, 303–312. [Google Scholar] [CrossRef] [PubMed]
  69. Chen, Z.; Salam, M.T.; Toledo-Corral, C.; Watanabe, R.M.; Xiang, A.H.; Buchanan, T.A.; Habre, R.; Bastain, T.M.; Lurmann, F.; Wilson, J.P.; et al. Ambient Air Pollutants Have Adverse Effects on Insulin and Glucose Homeostasis in Mexican Americans. Diabetes Care 2016, 39, 547–554. [Google Scholar] [CrossRef] [PubMed]
  70. Kramer, U.; Herder, C.; Sugiri, D.; Strassburger, K.; Schikowski, T.; Ranft, U.; Rathmann, W. Traffic-related air pollution and incident type 2 diabetes: Results from the SALIA cohort study. Environ. Health Perspect. 2010, 118, 1273–1279. [Google Scholar] [CrossRef] [PubMed]
  71. Kim, J.H.; Hong, Y.C. GSTM1, GSTT1, and GSTP1 polymorphisms and associations between air pollutants and markers of insulin resistance in elderly Koreans. Environ. Health Perspect. 2012, 120, 1378–1384. [Google Scholar] [CrossRef] [PubMed]
  72. Puett, R.C.; Hart, J.E.; Schwartz, J.; Hu, F.B.; Liese, A.D.; Laden, F. Are particulate matter exposures associated with risk of type 2 diabetes? Environ. Health Perspect. 2011, 119, 384–389. [Google Scholar] [CrossRef] [PubMed]
  73. Chen, L.; Zhou, Y.; Li, S.; Williams, G.; Kan, H.; Marks, G.B.; Morawska, L.; Abramson, M.J.; Chen, S.; Yao, T.; et al. Air pollution and fasting blood glucose: A longitudinal study in China. Sci. Total Environ. 2016, 541, 750–755. [Google Scholar] [CrossRef] [PubMed]
  74. Wang, Y.; Eliot, M.N.; Kuchel, G.A.; Schwartz, J.; Coull, B.A.; Mittleman, M.A.; Lipsitz, L.A.; Wellenius, G.A. Long-term exposure to ambient air pollution and serum leptin in older adults: Results from the MOBILIZE Boston study. J. Occup. Environ. Med. 2014, 56, e73–e77. [Google Scholar] [CrossRef] [PubMed]
  75. Eze, I.C.; Hemkens, L.G.; Bucher, H.C.; Hoffmann, B.; Schindler, C.; Kunzli, N.; Schikowski, T.; Probst-Hensch, N.M. Association between ambient air pollution and diabetes mellitus in Europe and North America: Systematic review and meta-analysis. Environ. Health Perspect. 2015, 123, 381–389. [Google Scholar] [CrossRef] [PubMed]
  76. Guyatt, G.H.; Oxman, A.D.; Montori, V.; Vist, G.; Kunz, R.; Brozek, J.; Alonso-Coello, P.; Djulbegovic, B.; Atkins, D.; Falck-Ytter, Y.; et al. GRADE guidelines: 5. Rating the quality of evidence—Publication bias. J. Clin. Epidemiol. 2011, 64, 1277–1282. [Google Scholar] [CrossRef] [PubMed]
  77. Guyatt, G.H.; Oxman, A.D.; Kunz, R.; Woodcock, J.; Brozek, J.; Helfand, M.; Alonso-Coello, P.; Falck-Ytter, Y.; Jaeschke, R.; Vist, G.; et al. GRADE guidelines: 8. Rating the quality of evidence—Indirectness. J. Clin. Epidemiol. 2011, 64, 1303–1310. [Google Scholar] [CrossRef] [PubMed]
  78. Clifford, A.; Lang, L.; Chen, R.; Anstey, K.J.; Seaton, A. Exposure to air pollution and cognitive functioning across the life course—A systematic literature review. Environ. Res. 2016, 147, 383–398. [Google Scholar] [CrossRef] [PubMed]
  79. Palacios, N.; Fitzgerald, K.; Roberts, A.L.; Hart, J.E.; Weisskopf, M.G.; Schwarzschild, M.A.; Ascherio, A.; Laden, F. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses’ health study cohort. Environ. Health Perspect. 2014, 122, 933–938. [Google Scholar] [CrossRef] [PubMed]
  80. Ailshire, J.A.; Crimmins, E.M. Fine particulate matter air pollution and cognitive function among older US adults. Am. J. Epidemiol. 2014, 180, 359–366. [Google Scholar] [CrossRef] [PubMed]
  81. Fung, K.Y.; Luginaah, I.N.; Gorey, K.M. Impact of air pollution on hospital admissions in Southwestern Ontario, Canada: Generating hypotheses in sentinel high-exposure places. Environ Health 2007, 6, 18. [Google Scholar] [CrossRef] [PubMed]
  82. Kunzli, N.; Tager, I.B. Air pollution: From lung to heart. Swiss Med. Wkly. 2005, 135, 697–702. [Google Scholar] [PubMed]
  83. Janghorbani, M.; Momeni, F.; Mansourian, M. Systematic review and meta-analysis of air pollution exposure and risk of diabetes. Eur. J. Epidemiol. 2014, 29, 231–242. [Google Scholar] [CrossRef] [PubMed]
  84. Thibault, V.; Belanger, M.; LeBlanc, E.; Babin, L.; Halpine, S.; Greene, B.; Mancuso, M. Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: A critical review and analysis. Diabetol. Metab. Syndr. 2016, 8, 71. [Google Scholar] [CrossRef] [PubMed]
  85. Robertson, M.; Seaton, A.; Whalley, L.J. Can we reduce the risk of dementia? QJM 2015, 108, 93–97. [Google Scholar] [CrossRef] [PubMed]
  86. Baldi, I.; Lebailly, P.; Mohammed-Brahim, B.; Letenneur, L.; Dartigues, J.F.; Brochard, P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am. J. Epidemiol. 2003, 157, 409–414. [Google Scholar] [CrossRef] [PubMed]
  87. Donaldson, K.; Brown, D.; Clouter, A.; Duffin, R.; MacNee, W.; Renwick, L.; Tran, L.; Stone, V. The pulmonary toxicology of ultrafine particles. J. Aerosol Med. 2002, 15, 213–220. [Google Scholar] [CrossRef] [PubMed]
  88. Johnston, H.J.; Verdon, R.; Gillies, S.; Brown, D.M.; Fernandes, T.F.; Henry, T.B.; Rossi, A.G.; Tran, L.; Tucker, C.; Tyler, C.R.; et al. Adoption of in vitro systems and zebrafish embryos as alternative models for reducing rodent use in assessments of immunological and oxidative stress responses to nanomaterials. Crit. Rev. Toxicol. 2018, 48, 252–271. [Google Scholar] [CrossRef] [PubMed]
  89. Duncan, B.B.; Schmidt, M.I.; Pankow, J.S.; Ballantyne, C.M.; Couper, D.; Vigo, A.; Hoogeveen, R.; Folsom, A.R.; Heiss, G.; Atherosclerosis Risk in Communities. Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2003, 52, 1799–1805. [Google Scholar] [CrossRef] [PubMed]
  90. Wellen, K.E.; Hotamisligil, G.S. Inflammation, stress, and diabetes. J. Clin. Investig. 2005, 115, 1111–1119. [Google Scholar] [CrossRef] [PubMed]
  91. Rehman, K.; Akash, M.S. Mechanisms of inflammatory responses and development of insulin resistance: How are they interlinked? J. Biomed. Sci. 2016, 23, 87. [Google Scholar] [CrossRef] [PubMed]
  92. Meigs, J.B. Multiple biomarker prediction of type 2 diabetes. Diabetes Care 2009, 32, 1346–1348. [Google Scholar] [CrossRef] [PubMed]
  93. Rioux, C.L.; Tucker, K.L.; Brugge, D.; Gute, D.M.; Mwamburi, M. Traffic exposure in a population with high prevalence type 2 diabetes—Do medications influence concentrations of C-reactive protein? Environ. Pollut. 2011, 159, 2051–2060. [Google Scholar] [CrossRef] [PubMed]
  94. Khafaie, M.A.; Salvi, S.S.; Ojha, A.; Khafaie, B.; Gore, S.S.; Yajnik, C.S. Systemic inflammation (C-reactive protein) in type 2 diabetic patients is associated with ambient air pollution in Pune City, India. Diabetes Care 2013, 36, 625–630. [Google Scholar] [CrossRef] [PubMed]
  95. Yang, B.Y.; Qian, Z.M.; Li, S.; Chen, G.; Bloom, M.S.; Elliott, M.; Syberg, K.W.; Heinrich, J.; Markevych, I.; Wang, S.Q.; et al. Ambient air pollution in relation to diabetes and glucose-homoeostasis markers in China: A cross-sectional study with findings from the 33 Communities Chinese Health Study. Lancet Planet Health 2018, 2, e64–e73. [Google Scholar] [CrossRef]
  96. Bolos, M.; Perea, J.R.; Avila, J. Alzheimer’s disease as an inflammatory disease. Biomol. Concepts 2017, 8, 37–43. [Google Scholar] [CrossRef] [PubMed]
  97. De Groot, N.S.; Burgas, M.T. Is membrane homeostasis the missing link between inflammation and neurodegenerative diseases? Cell Mol. Life Sci. 2015, 72, 4795–4805. [Google Scholar] [CrossRef] [PubMed]
  98. Morales, I.; Farias, G.; Maccioni, R.B. Neuroimmunomodulation in the pathogenesis of Alzheimer’s disease. Neuroimmunomodulation 2010, 17, 202–204. [Google Scholar] [CrossRef] [PubMed]
  99. Shepherd, C.; McCann, H.; Halliday, G.M. Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol. 2009, 118, 37–52. [Google Scholar] [CrossRef] [PubMed]
  100. Gupta, A.; Watkins, A.; Thomas, P.; Majer, R.; Habubi, N.; Morris, G.; Pansari, K. Coagulation and inflammatory markers in Alzheimer’s and vascular dementia. Int. J. Clin. Pract. 2005, 59, 52–57. [Google Scholar] [CrossRef] [PubMed]
  101. Koyama, A.; O’Brien, J.; Weuve, J.; Blacker, D.; Metti, A.L.; Yaffe, K. The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: A meta-analysis. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2013, 68, 433–440. [Google Scholar] [CrossRef] [PubMed]
  102. Jefferson, A.L.; Massaro, J.M.; Wolf, P.A.; Seshadri, S.; Au, R.; Vasan, R.S.; Larson, M.G.; Meigs, J.B.; Keaney, J.F., Jr.; Lipinska, I.; et al. Inflammatory biomarkers are associated with total brain volume: The Framingham Heart Study. Neurology 2007, 68, 1032–1038. [Google Scholar] [CrossRef] [PubMed]
  103. Calderon-Garciduenas, L.; Reed, W.; Maronpot, R.R.; Henriquez-Roldan, C.; Delgado-Chavez, R.; Calderon-Garciduenas, A.; Dragustinovis, I.; Franco-Lira, M.; Aragon-Flores, M.; Solt, A.C.; et al. Brain inflammation and Alzheimer’s-like pathology in individuals exposed to severe air pollution. Toxicol. Pathol. 2004, 32, 650–658. [Google Scholar] [CrossRef] [PubMed]
  104. Calderon-Garciduenas, L.; Azzarelli, B.; Acuna, H.; Garcia, R.; Gambling, T.M.; Osnaya, N.; Monroy, S.; Del Tizapantzi, M.R.; Carson, J.L.; Villarreal-Calderon, A.; et al. Air pollution and brain damage. Toxicol. Pathol. 2002, 30, 373–389. [Google Scholar] [CrossRef] [PubMed]
  105. Calderon-Garciduenas, L.; Maronpot, R.R.; Torres-Jardon, R.; Henriquez-Roldan, C.; Schoonhoven, R.; Acuna-Ayala, H.; Villarreal-Calderon, A.; Nakamura, J.; Fernando, R.; Reed, W.; et al. DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. Toxicol. Pathol. 2003, 31, 524–538. [Google Scholar] [CrossRef] [PubMed]
  106. Campbell, A.; Oldham, M.; Becaria, A.; Bondy, S.; Meacher, D.; Sioutas, C.; Misra, C.; Mendez, L.; Kleinman, M. Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology 2005, 26, 133–140. [Google Scholar] [CrossRef] [PubMed]
  107. Gerlofs-Nijland, M.E.; van Berlo, D.; Cassee, F.R.; Schins, R.P.; Wang, K.; Campbell, A. Effect of prolonged exposure to diesel engine exhaust on proinflammatory markers in different regions of the rat brain. Part. Fibre Toxicol. 2010, 7, 12. [Google Scholar] [CrossRef] [PubMed]
  108. Durga, M.; Devasena, T.; Rajasekar, A. Determination of LC50 and sub-chronic neurotoxicity of diesel exhaust nanoparticles. Environ. Toxicol. Pharmacol. 2015, 40, 615–625. [Google Scholar] [CrossRef] [PubMed]
  109. Cole, T.B.; Coburn, J.; Dao, K.; Roque, P.; Chang, Y.C.; Kalia, V.; Guilarte, T.R.; Dziedzic, J.; Costa, L.G. Sex and genetic differences in the effects of acute diesel exhaust exposure on inflammation and oxidative stress in mouse brain. Toxicology 2016, 374, 1–9. [Google Scholar] [CrossRef] [PubMed]
  110. Kim, S.Y.; Kim, J.K.; Park, S.H.; Kim, B.G.; Jang, A.S.; Oh, S.H.; Lee, J.H.; Suh, M.W.; Park, M.K. Effects of inhaled particulate matter on the central nervous system in mice. Neurotoxicology 2018, 67, 169–177. [Google Scholar] [CrossRef] [PubMed]
  111. Hullmann, M.; Albrecht, C.; van Berlo, D.; Gerlofs-Nijland, M.E.; Wahle, T.; Boots, A.W.; Krutmann, J.; Cassee, F.R.; Bayer, T.A.; Schins, R.P.F. Diesel engine exhaust accelerates plaque formation in a mouse model of Alzheimer’s disease. Part. Fibre Toxicol. 2017, 14, 35. [Google Scholar] [CrossRef] [PubMed]
  112. Morgan, T.E.; Davis, D.A.; Iwata, N.; Tanner, J.A.; Snyder, D.; Ning, Z.; Kam, W.; Hsu, Y.T.; Winkler, J.W.; Chen, J.C.; et al. Glutamatergic neurons in rodent models respond to nanoscale particulate urban air pollutants in vivo and in vitro. Environ. Health Perspect. 2011, 119, 1003–1009. [Google Scholar] [CrossRef] [PubMed]
  113. Solaimani, P.; Saffari, A.; Sioutas, C.; Bondy, S.C.; Campbell, A. Exposure to ambient ultrafine particulate matter alters the expression of genes in primary human neurons. Neurotoxicology 2017, 58, 50–57. [Google Scholar] [CrossRef] [PubMed]
  114. Gillespie, P.; Tajuba, J.; Lippmann, M.; Chen, L.C.; Veronesi, B. Particulate matter neurotoxicity in culture is size-dependent. Neurotoxicology 2013, 36, 112–117. [Google Scholar] [CrossRef] [PubMed]
  115. Campbell, A.; Daher, N.; Solaimani, P.; Mendoza, K.; Sioutas, C. Human brain derived cells respond in a type-specific manner after exposure to urban particulate matter (PM). Toxicol. In Vitro 2014, 28, 1290–1295. [Google Scholar] [CrossRef] [PubMed]
  116. Goldman, S.M. Environmental toxins and Parkinson’s disease. Annu. Rev. Pharmacol. Toxicol. 2014, 54, 141–164. [Google Scholar] [CrossRef] [PubMed]
  117. Niranjan, R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: Focus on astrocytes. Mol. Neurobiol. 2014, 49, 28–38. [Google Scholar] [CrossRef] [PubMed]
  118. Allen, K.V.; Frier, B.M.; Strachan, M.W. The relationship between type 2 diabetes and cognitive dysfunction: Longitudinal studies and their methodological limitations. Eur. J. Pharmacol. 2004, 490, 169–175. [Google Scholar] [CrossRef] [PubMed]
  119. Barbieri, M.; Boccardi, V.; Paolisso, G. Chapter 35—Cognitive Decline and Diabetes: A Focus on Linking Mechanisms. In Diet and Nutrition in Dementia and Cognitive Decline; Martin, C.R., Preedy, V.R., Eds.; Academic Press: San Diego, CA, USA, 2015; pp. 393–402. [Google Scholar]
  120. Craft, S. Insulin resistance syndrome and Alzheimer’s disease: Age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 2005, 26 (Suppl. 1), 65–69. [Google Scholar] [CrossRef]
  121. Accardi, G.; Caruso, C.; Colonna-Romano, G.; Camarda, C.; Monastero, R.; Candore, G. Can Alzheimer disease be a form of type 3 diabetes? Rejuvenat. Res. 2012, 15, 217–221. [Google Scholar] [CrossRef] [PubMed]
  122. Cheng, G.; Huang, C.; Deng, H.; Wang, H. Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Intern. Med. J. 2012, 42, 484–491. [Google Scholar] [CrossRef] [PubMed]
  123. Frisardi, V.; Solfrizzi, V.; Seripa, D.; Capurso, C.; Santamato, A.; Sancarlo, D.; Vendemiale, G.; Pilotto, A.; Panza, F. Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer’s disease. Ageing Res. Rev. 2010, 9, 399–417. [Google Scholar] [CrossRef] [PubMed]
  124. Garcia-Lara, J.M.; Aguilar-Navarro, S.; Gutierrez-Robledo, L.M.; Avila-Funes, J.A. The metabolic syndrome, diabetes, and Alzheimer’s disease. Revista de Investigacion Clinica Organo del Hospital de Enfermedades de la Nutricion 2010, 62, 343–349. [Google Scholar] [PubMed]
  125. Ohara, T.; Doi, Y.; Ninomiya, T.; Hirakawa, Y.; Hata, J.; Iwaki, T.; Kanba, S.; Kiyohara, Y. Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology 2011, 77, 1126–1134. [Google Scholar] [CrossRef] [PubMed]
  126. Adeghate, E.; Donath, T.; Adem, A. Alzheimer disease and diabetes mellitus: Do they have anything in common? Curr. Alzheimer Res. 2013, 10, 609–617. [Google Scholar] [CrossRef] [PubMed]
  127. Alam, F.; Islam, M.A.; Sasongko, T.H.; Gan, S.H. Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management. Curr. Pharm. Des. 2016, 22, 4430–4442. [Google Scholar] [CrossRef] [PubMed]
  128. D’Amelio, M.; Ragonese, P.; Callari, G.; Di Benedetto, N.; Palmeri, B.; Terruso, V.; Salemi, G.; Famoso, G.; Aridon, P.; Savettieri, G. Diabetes preceding Parkinson’s disease onset. A case-control study. Parkinsonism Relat. Disord. 2009, 15, 660–664. [Google Scholar] [CrossRef] [PubMed]
  129. Hu, G.; Jousilahti, P.; Bidel, S.; Antikainen, R.; Tuomilehto, J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 2007, 30, 842–847. [Google Scholar] [CrossRef] [PubMed]
  130. Yue, X.; Li, H.; Yan, H.; Zhang, P.; Chang, L.; Li, T. Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies. Medicine 2016, 95, e3549. [Google Scholar] [CrossRef] [PubMed]
  131. van Himbergen, T.M.; Beiser, A.S.; Ai, M.; Seshadri, S.; Otokozawa, S.; Au, R.; Thongtang, N.; Wolf, P.A.; Schaefer, E.J. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: Results from the Framingham Heart Study. Arch. Neurol. 2012, 69, 594–600. [Google Scholar] [CrossRef] [PubMed]
  132. Jayaraman, A.; Pike, C.J. Alzheimer’s disease and type 2 diabetes: Multiple mechanisms contribute to interactions. Curr. Diabetes Rep. 2014, 14, 476. [Google Scholar] [CrossRef] [PubMed]
  133. Cardoso, S.; Correia, S.; Santos, R.X.; Carvalho, C.; Santos, M.S.; Oliveira, C.R.; Perry, G.; Smith, M.A.; Zhu, X.; Moreira, P.I. Insulin is a two-edged knife on the brain. J. Alzheimer’s Dis. 2009, 18, 483–507. [Google Scholar] [CrossRef] [PubMed]
  134. Kleinridders, A.; Ferris, H.A.; Cai, W.; Kahn, C.R. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014, 63, 2232–2243. [Google Scholar] [CrossRef] [PubMed]
  135. Verdile, G.; Keane, K.N.; Cruzat, V.F.; Medic, S.; Sabale, M.; Rowles, J.; Wijesekara, N.; Martins, R.N.; Fraser, P.E.; Newsholme, P. Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer’s Disease. Mediat. Inflamm. 2015, 2015, 105828. [Google Scholar] [CrossRef] [PubMed]
  136. Diaz, J.; Martinez-Martin, P.; Rodriguez-Blazquez, C.; Vazquez, B.; Forjaz, M.J.; Ortiz, C.; Carmona, R.; Linares, C. Short-term association between road traffic noise and healthcare demand generated by Parkinson’s disease in Madrid, Spain. Gac. Sanit. 2017. [Google Scholar] [CrossRef] [PubMed]
  137. Cui, B.; Li, K.; Gai, Z.; She, X.; Zhang, N.; Xu, C.; Chen, X.; An, G.; Ma, Q.; Wang, R. Chronic Noise Exposure Acts Cumulatively to Exacerbate Alzheimer’s Disease-Like Amyloid-beta Pathology and Neuroinflammation in the Rat Hippocampus. Sci. Rep. 2015, 5, 12943. [Google Scholar] [CrossRef] [PubMed]
  138. Bakre, A.T.; Chen, R.; Khutan, R.; Wei, L.; Smith, T.; Qin, G.; Danat, I.M.; Zhou, W.; Schofield, P.; Clifford, A.; et al. Association between fish consumption and risk of dementia: A new study from China and a systematic literature review and meta-analysis. Public Health Nutr. 2018, 21, 1921–1932. [Google Scholar] [CrossRef] [PubMed]
  139. Balti, E.V.; Echouffo-Tcheugui, J.B.; Yako, Y.Y.; Kengne, A.P. Air pollution and risk of type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2014, 106, 161–172. [Google Scholar] [CrossRef] [PubMed]
  140. Oberdurster, G. Toxicology of ultrafine particles: In vivo studies. Philos. Trans. R. Soc. A 2000, 358, 2719–2740. [Google Scholar] [CrossRef]
  141. Zhang, R.; Dai, Y.; Zhang, X.; Niu, Y.; Meng, T.; Li, Y.; Duan, H.; Bin, P.; Ye, M.; Jia, X.; et al. Reduced pulmonary function and increased pro-inflammatory cytokines in nanoscale carbon black-exposed workers. Part. Fibre Toxicol. 2014, 11, 73. [Google Scholar] [CrossRef] [PubMed]
  142. Castranova, V.; Frazer, D.G.; Manley, L.K.; Dey, R.D. Pulmonary alterations associated with inhalation of occupational and environmental irritants. Int. Immunopharmacol. 2002, 2, 163–172. [Google Scholar] [CrossRef]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.